Results 131 to 140 of about 3,302 (197)

Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials. [PDF]

Rheumatology (Oxford)
Konzett V, Kerschbaumer A, Willmann L, Aletaha D.   +3 more
europepmc   +1 more source

Janus Kinase and Interleukin-6 Inhibitor-Induced Lipid Modulation and Its Association With Major Adverse Cardiovascular Events in Rheumatoid Arthritis: A Systematic Review of Clinical and Biomarker Evidence. [PDF]

Cureus
Patel RM, Dudley L, Morse M, Mihos CG, Kesselman MM.   +4 more
europepmc   +1 more source

Application of JAK inhibitors in the treatment of rheumatoid arthritis: a systematic analysis based on clinical trial databases and registries. [PDF]

Front Med (Lausanne)
Cao J, Huang R, Chen Y, Li X, Lou J, Xu L, Gu J, Luo Z, Yao T, Xie J.   +9 more
europepmc   +1 more source

The antitumor mechanism of oclacitinib in canine lymphoma. [PDF]

Sci Rep
Harada M, Inanaga S, Sakurai M, Shibutani S, Sugasawa T, Murayama N, Osumi T, Baba Y, Sakai H, Maeda S, Igase M, Mizuno T.   +11 more
europepmc   +1 more source

A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients? [PDF]

Curr Opin Lipidol
Muñoz Ayala K, Festen EAM, Westerterp M.   +2 more
europepmc   +1 more source

Tofacitinib-Induced Weight Gain in Context: comment on the article by Wollenhaupt et al. [PDF]

ACR Open Rheumatol
Palmowski A, Buttgereit F, Simon D, Kleyer A, Drzeniek NM.   +4 more
europepmc   +1 more source

JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease. [PDF]

Ther Adv Gastroenterol
Fousekis FS, Jefremow A, Katsanos KH, Neurath MF, Atreya R.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Evaluating filgotinib for the treatment of rheumatoid arthritis

Expert Opinion on Pharmacotherapy, 2021
Despite the availability of an extensive armamentarium, rheumatoid arthritis (RA) remains a therapeutic challenge for rheumatologists. Janus kinase inhibitors (JAKi) are an emerging class of targeted therapies. The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA.This review focuses on the ...
Marie-Elise Truchetet, Christophe Richez   +1 more
exaly   +4 more sources

Filgotinib for the treatment of Crohn’s disease

Expert Opinion on Investigational Drugs, 2018
Inflammatory bowel diseases, such as Crohn's disease (CD) and ulcerative colitis (UC), are widespread diseases (with an estimated 2.2 million Europeans affected), and even populations previously considered 'low risk' (such as Japan and India) are witnessing an increasing incidence.
Xavier Roblin, Stéphane Paul
exaly   +5 more sources